Abstract
IntroductionStatins reportedly have anti-inflammatory and anti-thrombotic effects aside from cholesterol-lowering. This study aimed to evaluate the effect of pre-existing statin use on platelet activation markers and clinical outcome in acute ischemic stroke patients.MethodsThis prospective study evaluated 172 patients with acute ischemic stroke divided in two groups: patients with pre-existing statin (n = 43) and without pre-existing statin (66 cases with statins initiated post-stroke and 63 without statin treatment). Platelet activation markers (CD62P and CD63) were measured by flow cytometry at different time points after stroke and analyzed with clinical outcome.ResultsThe CD62P and CD63 expressions on platelets were significantly lower in the patients with pre-existing statin use compared to the patients without pre-existing statin use on Day 1 post-stroke (p < 0.05). The CD62P expression was significantly lower in the patients with pre-existing statin use on 90 days after the acute stroke (p < 0.05). Patients with pre-existing statin use had lower incidences of early neurologic deterioration (END) than those without treatment (p < 0.05). Among several baseline clinical variables, admission NIHSS score, history of coronary artery disease, and pre-existing statin use were independent predictions of good clinical outcome at three months.ConclusionsPre-existing statin use is associated with decreased platelet activity as well as improved clinical outcome and reduced END in patients with acute ischemic stroke.
Highlights
Statins reportedly have anti-inflammatory and anti-thrombotic effects aside from cholesterollowering
The present study examined the expression of serial platelet activation markers (CD62P and CD63) and the three-month outcome after acute non-cardio-embolic ischemic stroke and produced four major findings
Longitudinal observational studies are warranted to evaluate the relation between dosage and choice of different statins in treating non-cardio-embolic stroke patients, to determine how to prevent early neurologic deterioration (END), and to improve neurologic outcome
Summary
Statins reportedly have anti-inflammatory and anti-thrombotic effects aside from cholesterollowering. This study aimed to evaluate the effect of pre-existing statin use on platelet activation markers and clinical outcome in acute ischemic stroke patients. A previous study demonstrates that platelet activity, measured by CD62P and CD63 expressions on platelets, are increased after acute ischemic stroke and reduced in patients who receive antiplatelet therapy [5,6,7]. Statin therapy has been shown to reduce cardiovascular events, including myocardial infarction, stroke, and death [14,15,16]. Early statin treatment may reduce the severity and improve the outcome of myocardial infarction, ischemic stroke, and intra-cerebral hemorrhage [17,18,19,20]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
